Display:
Providers:
Codex DNA, Inc. is a synthetic biology company focused on enabling researchers to build or write synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA). Its synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA, as well as the limitations of existing solutions that prevent the building of DNA and mRNA at a useable scale. Its BioXp system is an end-to-end automated workstation. It has developed and commercialized products, which include BioXp systems, including BioXp 3250 system, BioXp kits for generating an array of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. It has launched eight BioXp kits, three benchtop reagent kits, and various other synthetic biology products, including 14 SARS-CoV-2 full-length genomes and RNA controls, as well as its Vmax X2 cells. It has placed approximately 200 BioXp systems globally.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
March 28, 2022 | ||
---|---|---|
Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.
Copyright © 2022. All rights reserved.